TVTX · Travere Therapeutics, Inc. · Executive Compensation
$56.73
-0.12 (-0.21%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$5.60B
Shares
94.26M
Volume · Oct 2
522.72K
Avg daily vol (3M)
1.51M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $8,457,151 |
| Jula Inrig | Chief Medical Officer | $3,041,632 |
| Peter Heerma | Chief Commercial Officer | $2,261,751 |
| William Rote | Chief Research Officer | $2,256,465 |
| Christopher Cline | Chief Financial Officer | $2,250,914 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $5,204,877 |
| Jula Inrig | Chief Medical Officer | $1,681,277 |
| William Rote | Chief Research Officer | $1,516,646 |
| Peter Heerma | Chief Commercial Officer | $1,513,360 |
| Christopher Cline | Chief Financial Officer | $1,501,520 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $7,574,959 |
| William Rote | Chief Research Officer | $2,053,099 |
| Elizabeth E. Reed | Senior Vice President and General Council | $2,018,708 |
| Peter Heerma | Chief Commercial Officer | $2,003,914 |
| Jula Inrig | Chief Medical Officer | $2,001,539 |
| Christopher Cline | Chief Financial Officer | $1,971,490 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $5,753,490 |
| Jula Inrig | Chief Medical Officer | $2,866,793 |
| Christopher Cline | Chief Financial Officer | $2,325,646 |
| William Rote | Chief Research Officer | $2,033,381 |
| Peter Heerma | Chief Commercial Officer | $2,005,747 |
| Elizabeth E. Reed | Senior Vice President and General Council | $1,998,516 |
| Laura Clague | Former Chief Financial Officer | $1,963,343 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $5,739,010 |
| Noah Rosenberg | Former Chief Medical Officer | $2,780,608 |
| William Rote | Senior Vice President and Head of Research and Development | $1,946,740 |
| Laura Clague | Former Chief Financial Officer | $1,934,671 |
| Elizabeth E. Reed | Senior Vice President and General Council | $1,891,071 |
| Peter Heerma | Chief Commercial Officer | $1,880,976 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $5,447,879 |
| William Rote | Senior Vice President and Head of Research and Development | $1,657,674 |
| Noah Rosenberg | Former Chief Medical Officer | $1,655,032 |
| Laura Clague | Former Chief Financial Officer | $1,648,714 |
| Elizabeth E. Reed | Senior Vice President, General Counsel and Corporate Secretary | $1,601,191 |
| Peter Heerma | Chief Commercial Officer | $1,532,290 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Eric Dube | President, Chief Executive Officer and Director | $9,679,319 |
| Noah Rosenberg | Former Chief Medical Officer | $1,369,643 |
| Peter Heerma | Chief Commercial Officer | $1,325,278 |
| William Rote | Senior Vice President and Head of Research and Development | $1,310,226 |
| Laura Clague | Senior Vice President and Chief Financial Officer | $1,303,582 |
| Elizabeth E. Reed | Senior Vice President, General Counsel and Corporate Secretary | $1,258,447 |
| Stephen Aselage | Director and Former President and Chief Executive Officer | $1,039,269 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen Aselage | Director and Former President and Chief Executive Officer | $4,602,287 |
| Noah Rosenberg | Chief Medical Officer | $2,403,083 |
| Laura Clague | Senior Vice President and Chief Financial Officer | $1,860,308 |
| William Rote | Senior Vice President and Head of Research and Development | $1,618,525 |
| Elizabeth E. Reed | Senior Vice President, General Counsel and Corporate Secretary | $1,581,261 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Stephen Aselage | Director and Former President and Chief Executive Officer | $3,428,325 |
| William Rote | Senior Vice President and Head of Research and Development | $1,853,644 |
| Laura Clague | Senior Vice President and Chief Financial Officer | $1,496,638 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Bradley Campbell | Board of Directors | Appointed | 2026-09-21 |
| Bradley Campbell | President and Chief Executive Officer | Appointed | 2026-09-21 |
| Bradley L. Campbell | President and Chief Executive Officer | Appointed | 2026-09-21 |
| Bradley L. Campbell | member of the Board of Directors | Appointed | 2026-09-21 |
| Eric Dube, Ph.D. | member of the Board of Directors | Resigned | 2026-09-21 |
| Eric Dube, Ph.D. | President and Chief Executive Officer | Resigned | 2026-09-21 |
| Jula Inrig | Executive Vice President, Head of Research & Development and Chief Medical Officer | Appointed | 2026-06-16 |
| William Rote | Chief Research Officer | Retired | 2026-06-16 |
| Ruth Williams-Brinkley | Director | Appointed | 2025-05-16 |
| Ron Squarer | Director | Appointed | 2025-05-16 |
| Sandra Poole | Director | Appointed | 2025-05-16 |
| John A. Orwin | Director | Appointed | 2025-05-16 |
| Jeffrey Meckler | Director | Appointed | 2025-05-16 |
| Eric Dube | Director | Appointed | 2025-05-16 |
| Gary Lyons | Director | Appointed | 2025-05-16 |
| Timothy Coughlin | Director | Appointed | 2025-05-16 |
| Suzanne Bruhn | Director | Appointed | 2025-05-16 |
| Roy D. Baynes | Director | Appointed | 2025-05-16 |
| Sandra Poole | Director | Appointed | 2024-05-13 |
| Ruth Williams-Brinkley | Director | Appointed | 2024-05-13 |
| Ron Squarer | Director | Appointed | 2024-05-13 |
| Eric Dube | Director | Appointed | 2024-05-13 |
| Gary Lyons | Director | Appointed | 2024-05-13 |
| Jeffrey Meckler | Director | Appointed | 2024-05-13 |
| John A. Orwin | Director | Appointed | 2024-05-13 |